Scott L. Burrows, Chief Financial Officer at Spyre Therapeutics, Inc. (SYRE), sold 7,500 shares at $49.21 ($370K) on 2026-04-01, disclosed to the SEC on 2026-04-03.
Scheduled sale ($370k) by Chief Financial Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $49.21 | 6,200 | $305K | 82.4% |
| 2 | $49.98 | 1,300 | $65K | 17.6% |
| Total | $49.34 avg | 7,500 | $370K | 100% |
| Filing → |
| SYRE | SELL | 2026-08-05 | $717K | — | Filing → |
| SYRE | SELL | 2026-07-02 | $658K | — | Filing → |
| SYRE | SELL | 2026-06-26 | $1.3M | — | Filing → |